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glucose tolerance test, we determined insulin kinetics parameters and selected
standardized kinetic parameters based on mean values in a selected subgroup. We
computed ISR from insulin concentration during the oral glucose tolerance test using
these parameters and compared ISR with the standard C-peptide deconvolution approach.
We then performed the same comparison in an independent data set (231 subjects). In the
first data set, total ISRs from insulin and C-peptide were highly correlated (R2 = 0.75, P <
.0001), although on average different (103 ± 6 vs 108 ± 3 nmol, P < .001). Good correlation was
also found in the second data set (R2 = 0.54, P < .0001). The insulin method somewhat
overestimated total ISR (85 ± 5 vs 67 ± 3 nmol, P = .002), in part because of differences in
insulin assay. Similar results were obtained for fasting ISR. Despite the modest bias, the
insulin and C-peptide methods were consistent in predicting differences between groups
(eg, obese vs nonobese) and relationships with other physiological variables (eg, body mass
index, insulin resistance). The insulin method estimated first-phase ISR peak similarly to
the C-peptide method and better than the simple use of insulin concentration. The insulin-
based ISR method compares favorably with the C-peptide approach. The method will be
particularly useful in data sets lacking C-peptide to assess β-cell function through models
requiring prehepatic secretion.
© 2011 Elsevier Inc. All rights reserved.study, data analysis, data interpretation, manuscript writing; GP: data interpretation,
G: data collection; RADeF: data collection, data interpretation; EF: data interpretation; AM:
uscript writing.
Uniti, 4, 35127 Padova, Italy. Tel.: +39 049 829 5786; fax: +39 049 829 5763.
er Inc. All rights reserved.
al, Estimation of prehepatic insulin secretion: comparison between standardized
etabolism (2011), doi:10.1016/j.metabol.2011.08.001
2 M E T A B O L I S M C L I N I C A L A N D E X P E R I M E N T A L X X ( 2 0 1 1 ) X X X – X X X1. Introduction
The assessment of insulin secretion is of primary importance in
the study of glucose homeostasis and its disturbances. Insulin
secreted by the pancreatic β-cells enters the liver through the
portalvein,where it is cleared fromcirculation. Insulinescaping
hepatic removal reaches the peripheral circulation via the
hepatic veins and sustains insulin concentration measured in
plasma. Thus, peripheral insulin delivery (also denoted as
peripheral or posthepatic insulin secretion) is a fraction of the
actual pancreatic secretion (also denoted as prehepatic or
endogenous insulin secretion). C-peptide, which is co-secreted
with insulin in equimolar amounts, is not removed by the liver
to a significant extent; and thus, peripheral C-peptide delivery
equals prehepatic insulin secretion. In addition, the linearity of
C-peptide kinetics has justified the use of deconvolution of
plasma C-peptide concentration as the reference method for
the calculation of prehepatic insulin secretion [1].
However, in several large cohorts, plasma C-peptide con-
centration has not been measured; and this has prevented the
study of β-cell function with approaches requiring the knowl-
edge of the actual insulin secretion [2]. Thus, it would be useful
to have amethod to calculate insulin secretion from the plasma
insulin. Past attempts to calculate insulin secretion by decon-
volution of plasma insulin concentration have provided
important information [3,4]. However, these methods calculat-
ed the delivery of insulin to the peripheral circulation and not
the prehepatic insulin secretion rate (ISR).We sought to present
an insulin-based deconvolution method, using the same logic
as the traditional C-peptide approach [5], and to compare this
method to the C-peptide approach. To accomplish our aims, we
derived a standardized insulin kinetics model from an insulin-
modified intravenous glucose tolerance test (IVGTT) and
determined insulin secretion using both the C-peptide ap-
proach and the insulin kinetic model. We then compared the
results of the 2methods in a separate large data set inwhich an
oral glucose tolerance test (OGTT) was performed.2. Methods
2.1. Subjects: Vienna and San Antonio data sets
The Vienna data set included 134 women, 98 of whom had a
history of gestational diabetes and 36 had normal pregnancy.
All women were recruited from the outpatient department of
the University Clinic of Vienna and gave written informed
consent for participation in the study, which was approved by
the local Ethics Committee. Subjects were studied 4 to
6 months after delivery (they were not breast-feeding at the
time). Among the women with former gestational diabetes,
75 had normal glucose tolerance (NGT), 18 had impaired
glucose regulation (IGR) (impaired fasting glucose and/or
impaired glucose tolerance), and 5 had type 2 diabetes
mellitus (T2DM) according to the American Diabetes Associ-
ation 1997 criteria; 64 women were lean (body mass index
[BMI] <25 kg/m2), 33 were overweight (BMI ≥25 and <30 kg/m2),
and 37 were obese (BMI ≥30 kg/m2). Some of these subjects
have been included in a previous report [6].Please cite this article as: Tura A, et al, Estimation of prehe
C-peptide and insulin kinetic models, Metabolism (2011), doi:10The San Antonio data set included 231 subjects (109 men,
122 women). All subjects were studied on the Clinical
Research Center of the University of Texas Health Science
Center, San Antonio, TX. The study protocol was approved by
the Institutional Review Board of the University of Texas
Health Science Center, San Antonio; and informed written
consent was obtained from all subjects before their participa-
tion. Among the studied subjects, 44 had NGT, 22 had IGR, and
165 had T2DM. Based upon their BMI, 21 subjects were lean, 90
were overweight, and 120 were obese. All subjects had normal
liver and kidney function. These subjects have been included
in a previous study [7].
2.2. Metabolic tests
After a 10- to 12-hour overnight fast, all subjects in the Vienna
data set underwent an insulin-modified IVGTT. Glucose
(300 mg/kg) was injected at time 0 to 0.5 minute, and insulin
(0.03 IU/kg) was infused intravenously at time 20minutes over
1 minute. Venous blood samples for determination of plasma
concentration of glucose, insulin, and C-peptide were collect-
ed at baseline and at 3, 4, 5, 6, 8, 10, 14, 19, 22, 27, 30, 35, 40, 50,
70, 100, 140, and 180 minutes after glucose injection. On a
separate day, the same subjects underwent a standard 75-g
OGTT. Venous blood sampleswere collected at baseline and at
10, 20, 30, 60, 90, 120, 150, and 180 minutes. Insulin (Serono
Diagnostics, Freiburg, Germany) and C-peptide (CIS Bio
International, Gif-sur-Yvette, France) were determined in
duplicate by commercially available radioimmunoassay kits.
Similarly, after an overnight fast, all the subjects in the San
Antonio data set underwent a 75-g OGTT; and blood samples
were collected at −30, −15, 0, 30, 60, 90, and 120minutes for the
measurement of plasma glucose, insulin, and C-peptide.
Some of the subjects (175 of 231) also underwent a euglycemic
insulin clamp for determination of the rate of glucose
disappearance (M value) [7]. Plasma insulin and C-peptide
concentrations were measured by radioimmunoassay using
specific kits (Linco Research, St Louis, MO).
2.3. Calculation of insulin kinetic parameters from the
IVGTT in the Vienna data set
During the insulin-modified IVGTT, insulin enters the periph-
eral circulation exogenously from the infusion at 20 minutes
as well as from the release of endogenously secreted insulin
from 0 to 180 minutes, after passage through the liver. The
posthepatic insulin delivery, ISRPE(t), is a fraction of prehepatic
insulin secretion, ISR(t); that is, ISRPE(t) = F(t)ISR(t), with F(t)
between 0 and 1. We described insulin kinetics with a linear
model relating the plasma insulin concentration to peripheral
insulin appearance, that is, the sum of exogenous insulin
infusion, IINF(t), and posthepatic insulin delivery, ISRPE(t).
Thus, insulin concentration, IC(t), is the convolution of the
impulse response of the linear insulin kinetic model, h(t), and
IINF(t) + F(t)ISR(t):
IC tð Þ = h tð Þ  IINF tð Þ + F tð ÞISR tð Þ½ ; ð1Þ
where ⊗ is the convolution operator. This approach involves
an approximation, as it assumes that the time-varying hepatic
insulin fractional extraction, 1 − F(t), affects the peripheralpatic insulin secretion: comparison between standardized
.1016/j.metabol.2011.08.001
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and h(t) (see “Discussion” for further comments).The
insulin kinetic impulse response was represented using the
2-exponential function:
h tð Þ = 1 =ClINSPE  W  a  e−at + 1 −Wð Þ  b  e−bt
  ð2Þ
where ClINSPE is the peripheral (posthepatic) insulin clearance
andW is the relative contribution of the first exponential term
to the clearance (as the term in parentheses has unit integral
and W is the fraction due to the first exponential).
Because the exogenous insulin infusion IINF(t) is known
(1-minute infusion of known dose at 20 minutes of the IVGTT)
and the prehepatic insulin secretion ISR(t) can be calculated
fromC-peptide deconvolution using themethod by Van Cauter
et al [5], it is possible to estimate the parameters of h(t) and F(t)
from the plasma insulin concentration by using least squares,
with the addition of a regularization term to obtain a smooth F
(t) (represented as a piecewise-linear function of time).
The factor F(t) obtained from the IVGTT analysis is specific
for this test. To obtain a model by which insulin secretion can
be computed from plasma insulin concentration by deconvo-
lution in the general case, as in the approach of Van Cauter
et al, we used the mean value of F(t), F―. Thus, the insulin
kinetic impulse response used for deconvolution of the
plasma insulin curve is the function:
r tð Þ = 1=ClINS  W  a  e−at + 1 −Wð Þ  b  e−bt
 
; ð3Þ
where ClINS =
ClINSPE
P
F
represents prehepatic insulin clearance.
To derive a standardized insulin kinetic model along the
same approach used by Van Cauter et al, we tested the
relationships between the individual insulin kinetic parame-
ters (ClINS, W, α, β, and F
―) and the anthropometric data.
Because no significant relationship was found (“Results”), we
adopted the mean group values as standardized parameters.Table 1 – Subjects' characteristics in the Vienna and San Anton
Vienna data set
NGT IGR
n 111 18
Age (y) 32.5 ± 0.5 35.2 ± 1.1
BMI (kg/m2) 26.0 ± 0.5 30.2 ± 1.2
Sex (M/F) 0/111 0/18
OGTT
Basal glucose (mmol/L) 4.76 ± 0.04 5.48 ± 0.15
Basal insulin (pmol/L) 57.0 ± 3.4 62.2 ± 5.2
Basal C-peptide (pmol/L) 596 ± 24 748 ± 87
Mean glucose (mmol/L) 5.97 ± 0.07 7.93 ± 0.23
Mean insulin (pmol/L) 248 ± 14 259 ± 24
Mean C-peptide (pmol/L) 1833 ± 57 1975 ± 109
Basal C-peptide to insulin ratio 11.8 ± 0.4 11.2 ± 0.6
Mean C-peptide to insulin ratio 8.6 ± 0.3 8.1 ± 0.5
IVGTT
Basal glucose (mmol/L) 4.72 ± 0.04 5.29 ± 0.13
Basal insulin (pmol/L) 53.5 ± 3.3 57.8 ± 4.1
Basal C-peptide (pmol/L) 582 ± 24 694 ± 71
Mean glucose (mmol/L) 9.04 ± 0.11 10.83 ± 0.51
Mean insulin (pmol/L) 503 ± 23 523 ± 43
Mean C-peptide (pmol/L) 1208 ± 49 1278 ± 118
Please cite this article as: Tura A, et al, Estimation of prehe
C-peptide and insulin kinetic models, Metabolism (2011), doi:10To avoid a possible disturbing influence from the subjects in
whom the agreement between insulin secretion calculated
fromC-peptide and insulinwas not satisfactory, we calculated
mean parameters in a selected group, as explained in the
following section.
In the standardized parameters, insulin clearance was
given in liters per minute per square meter of body surface
area (BSA). Therefore, the insulin deconvolution method
calculates insulin secretion in picomoles per minute per
square meter, whereas the insulin concentration is in
picomoles per liter. However, when comparing the insulin
and C-peptide deconvolution methods, insulin secretion was
expressed in picomoles per minute, as in the approach of Van
Cauter et al, by multiplying by BSA.
2.4. Calculation of insulin secretion from OGTT plasma
insulin values in the Vienna data set and parameter
determination for the standardized insulin kinetic model
Insulin secretion was calculated from the OGTT plasma
C-peptide curves of the Vienna data set with the approach of
Van Cauter et al [5]. Briefly, with this method, insulin secretion
is determined by deconvolution from plasma C-peptide con-
centration using individualized C-peptide kinetic parameters
(distribution volume, short and longhalf-life, and short half-life
associated fraction). Parameters are determined for each
subject based on anthropometric data and diabetes status.
Insulin secretion from the approach of Van Cauter et al was
compared with insulin secretion obtained from plasma
insulin levels using the individual parameters of insulin
kinetics (ClINS, W, α, β, and F
―). From the insulin secretion
profiles, basal insulin secretion and total insulin secretion
(ie, the integral during the OGTT) were calculated.
Based on the comparison between insulin secretion
obtained from C-peptide and insulin, a subgroup of subjectsio data sets (mean ± SE)
San Antonio data set
T2DM NGT IGR T2DM
5 44 22 165
34.2 ± 1.7 37.0 ± 1.9 42.0 ± 2.8 52.4 ± 0.8
31.4 ± 3.1 29.6 ± 0.9 31.7 ± 0.9 31.3 ± 0.4
0/5 18/26 9/13 82/83
6.83 ± 0.47 5.24 ± 0.05 5.56 ± 0.11 10.20 ± 0.22
97.4 ± 43.5 60.4 ± 5.9 80.0 ± 6.5 116 ± 7
759 ± 187 677 ± 52 849 ± 54 932 ± 36
10.25 ± 0.49 6.75 ± 0.14 8.39 ± 0.15 15.51 ± 0.25
320 ± 118 410 ± 38 554 ± 65 259 ± 20
1845 ± 334 2104 ± 134 2413 ± 177 1494 ± 67
11.7 ± 3.4 12.6 ± 0.7 11.5 ± 0.8 9.7 ± 0.5
7.2 ± 1.1 5.8 ± 0.3 5.2 ± 0.5 7.4 ± 0.3
6.84 ± 0.28 – – –
86.4 ± 29.7 – – –
673 ± 137 – – –
12.07 ± 0.73 – – –
474 ± 84 – – –
904 ± 189 – – –
patic insulin secretion: comparison between standardized
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Table 2 – Insulin kinetic parameters computed in the
whole Vienna data set and in the group of subjects
meeting the quality criteria (mean ± SE)
Whole Vienna
data set (N = 134)
Vienna data set
selection (n = 74)
ClINSPE (L/min) 0.68 ± 0.02 0.68 ± 0.03
ClINS (L/min) 1.82 ± 0.06 1.85 ± 0.06
ClINSBSA (L min
−1 m−2) 1.00 ± 0.03 1.01 ± 0.04
W (dimensionless) 0.52 ± 0.03 0.54 ± 0.04
α (1/min) 0.63 ± 0.05 0.58 ± 0.06
β (1/min) 0.08 ± 0.01 0.08 ± 0.01
ClCP (L/min) 0.24 ± 0.01 0.24 ± 0.01
F
―
(dimensionless) 0.38 ± 0.01 0.37 ± 0.01
The standardized insulin kinetic parameters for Eq. (3) are in bold.
4 M E T A B O L I S M C L I N I C A L A N D E X P E R I M E N T A L X X ( 2 0 1 1 ) X X X – X X Xin which the agreement was best was selected to obtain more
robust mean parameters for the standardized insulin kinetic
model. The following quality criteria were used: (a) basal and
total insulin secretion from insulin not exceeding twice the
basal secretion from C-peptide, and vice versa; (b) ratio of
basal C-peptide to basal insulin (from OGTT and IVGTT) not
exceeding twice the ratio of insulin to C-peptide clearances,
and vice versa; and (c) ratio of the OGTT areas under the curve
of C-peptide and insulin not exceeding twice the ratio of
insulin to C-peptide clearances, and vice versa.
We selected the mean parameters in this group as
standardized parameters for the insulin kinetic model of
Eq. (3). We then recalculated insulin secretion in all the
subjects of this study with this model and using the same
deconvolution method used for C-peptide analysis.
2.5. Calculation of insulin secretion from OGTT plasma
insulin in the San Antonio data set
In the San Antonio data set, we calculated insulin secretion
from plasma insulin concentration with the standardized
insulin kinetic model and from plasma C-peptide concentra-0  0.5 1 1.5 2 2.5 3
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Fig. 1 – Insulin secretion from the plasma C-peptide
concentration during the IVGTT in the Vienna data set
(mean ± SE); the inset shows insulin secretion during the first
20 minutes from plasma C-peptide (solid, thin line) and from
plasma insulin, with individual kinetic parameters (dashed
line) and mean kinetic parameters (solid, thick line) (top).
Pattern of F(t) parameter during the IVGTT in the Vienna data
set (mean ± SE) (bottom).
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comparison was performed.
2.6. Statistical analysis
Data are given as mean ± SE unless otherwise specified.
Linear regression analysis was performed by standard
techniques. Differences were tested using paired or unpaired
t test, as appropriate, on logarithmically transformed values.0  0.5 1 1.5 2 2.5 3
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Fig. 2 – Insulin secretion from plasma C-peptide (dashed line)
and plasma insulin (solid line) in the Vienna data set (top).
Plasma insulin concentration is also reported (bottom). Data
are mean ± SE.
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Bland-Altman analyses were also performed.3. Results
3.1. Insulin secretion and kinetic parameters from the
IVGTT in the Vienna data set
The subjects' characteristics in the Vienna data set are
reported in Table 1. Insulin secretion from C-peptide during
the IVGTT in the whole data set is shown in Fig. 1 (top). The
mean values for the insulin kinetic parameters are shown in
Table 2 (left column). The pattern of factor F(t) is reported in
Fig. 1 (bottom). By either univariate or multivariate regression
analysis, we did not find significant relationships between the
insulin kinetic parameters and anthropometric data (age, BMI,
BSA, lean bodymass) or metabolic parameters (glucose levels,
insulin sensitivity computed with the homeostasis model
assessment of insulin resistance [8], and insulin sensitivity
index from minimal model analysis [9]). After calculation of
insulin secretion during the OGTT (see below), 74 subjectsmet
the quality criteria specified in “Methods.” The mean insulin
kinetic parameters in these selected subjects are reported in
Table 2 (right column); these mean values are the standard-
ized insulin kinetic parameters used throughout this analysis.
As can be appreciated from Table 2, the subject selection was
virtually without effect on the mean values.0 100 200 300 400 500 600
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Please cite this article as: Tura A, et al, Estimation of prehe
C-peptide and insulin kinetic models, Metabolism (2011), doi:10The inset of Fig. 1 shows the comparison of the insulin
secretion profiles obtained from plasma C-peptide and from
plasma insulin during the first 20 minutes of the IVGTT, that
is, before insulin injection, in the whole Vienna data set.
Insulin secretion rates calculated from C-peptide and those
derived from insulin using the individual kinetic parameters
were very similar, although the insulin peak was delayed by
approximately 1 minute on average. When using mean
kinetic parameters, the results deteriorated only slightly
(the peak value was somewhat lower). The acute insulin
secretory response (AIR), computed as the mean increase
above baseline over the initial 0- to 8-minute interval, was
784 ± 37 pmol/min using C-peptide, 635 ± 45 pmol/min
using insulin with individual kinetic parameters, and 627 ±
45 pmol/min with the standardized insulin parameters. By
regression analysis, AIR from C-peptide was significantly
related to the AIR from insulin with both individual (R2 = 0.46,
P < .0001) and standardized parameters (R2 = 0.61, P < .0001).
In the group of subjects with NGT (Table 1), the minimal
model insulin sensitivity index was weakly but consistently
related in a reciprocal fashion to logarithmically trans-
formed AIR values calculated with all methods (C-peptide:
R2 = 0.06, P = .008; insulin with individual parameters: R2 =
0.05, P = .015; insulin with standardized parameters: R2 = 0.11,
P = .0003). Peak insulin secretion (Fig. 1), expressed as the
ratio to the basal value, was similar with all methods (14- to
16-fold), but considerably higher than the peak insulin
concentration (∼6-fold).0 100 200 300 400 500 600
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Fig. 4 – Insulin secretion from plasma C-peptide (dashed line)
and plasma insulin (solid line) in the San Antonio data set
(top). Plasma insulin concentration is also reported (bottom).
Data are mean ± SE.
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As shown in Fig. 2 (top), insulin secretion calculated from
the plasma insulin concentration using standardized pa-
rameters agreed closely with that derived from C-peptide
analysis. Plasma insulin concentration was also reported
(Fig. 2, bottom).
Mean basal and total insulin secretions from C-peptide
were 158 ± 7 pmol/min and 108 ± 3 nmol, respectively. The
corresponding values obtained from insulin were 113 ±
8 pmol/min and 100 ± 6 nmol with the individual insulin
kinetic parameters and 119 ± 8 pmol/min and 103 ± 6 nmol
with the standardized parameters. Although modest, the
differences between the C-peptide method and the standard-
ized insulin method were statistically significant (P < .001).
However, regression analysis showed a strong relationship
between secretion rates from C-peptide and from insulin (R2 =
0.71 for basal secretion, R2 = 0.75 for total secretion, both P <
.0001; Fig. 3). This correlation was similar to that found
between C-peptide and insulin levels at fasting and during the
OGTT (R2 = 0.63 for the fasting values, R2 = 0.71 for the OGTT
area under the curves, P < .0001). Bland-Altman analysis of
these data showed that only a limited number of samples
were outside the limits of agreement (average difference ± 1.96
standard deviation of the difference), that is, only 5 of 134
samples for total insulin secretion and 7 samples for basal
secretion (Fig. 3, right).
3.3. Insulin secretion from the OGTT in the San Antonio
data set
The subjects' characteristics in the San Antonio data set are
reported in Table 1. Furthermore, Table 1 compares the
glucose, insulin, and C-peptide levels in the Vienna and San
Antonio subjects divided according to their glucose tolerance.
The groups of corresponding glucose tolerance were relatively
homogeneous, except for the diabetic patients. There was a
significant difference in the plasma C-peptide to insulin ratios
(8.59 ± 0.24 vs 6.82 ± 0.22, P < .0001, for ratios of area under
curves), which most likely is explained by the different
C-peptide and insulin assays used in Vienna and San Antonio.
This clearly affects the relationship between the C-peptide
and the insulin method for calculation of insulin secretory
rate in this data set. As a consequence, higher ISRs were
obtained with the insulin method as compared with the
C-peptide method (Fig. 4, top). Plasma insulin concentration
was also reported (Fig. 4, bottom).
Fig. 5 shows the regression analysis and the Bland-Altman
plot for basal and total insulin secretion. The overall
correlation coefficients were R2 = 0.45 and R2 = 0.54 for basal
and total secretion, respectively (P < .0001). The slope of the
regression line was not different from unity (95% confidence
interval [CI], 0.98-1.31) for basal secretion, whereas it was
greater than 1 for total insulin secretion (95% CI, 1.23-1.56).
The difference between basal insulin secretion calculated
from the plasma C-peptide and insulin concentrations,
although small, was statistically significant (225 ± 8 vs 228 ±
13 pmol/min, respectively, P = .02); a significant difference also
was found for total insulin secretion (67 ± 3 vs 85 ± 5 nmol, P =
.002). However, according to the Bland-Altman analysis, onlyPlease cite this article as: Tura A, et al, Estimation of prehe
C-peptide and insulin kinetic models, Metabolism (2011), doi:107 of 231 samples for basal insulin secretion and 9 samples for
total insulin secretion fell outside the limits of agreement.
In the NGT subjects, we also investigated whether insulin
secretion calculated from the plasma insulin and C-peptide
concentrations showed similar relationships with the BMI and
insulin sensitivity (M value). After logarithmic transformation
of the variables, basal insulin secretion from either C-peptide
or insulin was directly related to BMI (R2 = 0.34 for C-peptide,
R2 = 0.53 for insulin, P < .0001); similar results were found for
total insulin secretion (R2 = 0.22, R2 = 0.52, P < .0012). Inverse
relationships were found between basal and total insulin
secretion and the M value both with the C-peptide and with
the insulin method (R2 = 0.34, R2 = 0.31 basal secretion; R2 =
0.28, R2 = 0.36 total secretion; P < .0009).
3.4. Insulin secretion in subgroups of the San Antonio
data set
As summarized in Table 3, results in subgroups were in
general agreement with those in the whole data set. Notably,
despite absolute differences in ISRs calculated from the
plasma C-peptide and insulin methods, the differences
between groups were consistently detected with both ap-
proaches. Thus, with both methods, basal insulin secretion
was higher in diabetic than nondiabetic subjects (P < .03 for
both), whereas the opposite was true for stimulated totalpatic insulin secretion: comparison between standardized
.1016/j.metabol.2011.08.001
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Fig. 5 – Basal (top panels) and total (bottom panels) insulin secretion from plasma C-peptide and insulin concentrations in the
subjects from the San Antonio data set. The left panels show the correlations (regression equations are reported); the right
panels show the corresponding Bland-Altman plots. Subjects are divided into diabetic (circle) and nondiabetic (square) groups.
Table 3 – Comparison of basal and total insulin secretion from plasma C-peptide and insulin concentrations in subjects of
the San Antonio data set divided according to different criteria
Secretion from
C-peptide
Secretion
from insulin
Regression analysis
slope (95% CI), R2
Bland-Altman analysis N1/N2
(samples over total out of agreement limits)
Basal secretion (pmol/min)
Diabetic subjects 238 ± 9 252 ± 17 (0.98-1.39), R2 = 0.44 6/165
Nondiabetic subjects 192 ± 11 166 ± 13 (0.56-1.03), R2 = 0.41 4/66
Obese subjects a 265 ± 11 297 ± 22 (0.98-1.55), R2 = 0.41 5/120
Nonobese subjects 184 ± 9 157 ± 10 (0.56-0.87), R2 = 0.42 7/111
Men 218 ± 10 214 ± 15 (0.83-1.23), R2 = 0.50 5/109
Women 231 ± 11. 240 ± 21 (0.96-1.47), R2 = 0.43 3/122
Young subjects b 215 ± 12 200 ± 15 (0.49-1.02), R2 = 0.37 2/60
Elderly subjects 204 ± 12 212 ± 17 (0.71-1.21), R2 = 0.47 3/67
Insulin-resistant subjects c 276 ± 16 265 ± 23 (0.48-1.20), R2 = 0.35 3/44
Insulin-sensitive subjects 158 ± 9 130 ± 12 (0.48-1.10), R2 = 0.40 2/43
Total secretion (nmol)
Diabetic subjects 56 ± 3 68 ± 5 (1.13-1.47), R2 = 0.58 10/165
Nondiabetic subjects 93 ± 5 130 ± 12 (0.96-1.90), R2 = 0.37 4/66
Obese subjects a 74 ± 5 106 ± 9 (1.15-1.63), R2 = 0.54 5/120
Nonobese subjects 59 ± 3 64 ± 5 (1.02-1.46), R2 = 0.52 1/111
Men 63 ± 4 80 ± 8 (1.20-1.71), R2 = 0.55 5/109
Women 69 ± 4 90 ± 7 (1.10-1.55), R2 = 0.54 4/122
Young subjects b 79 ± 6 109 ± 12 (0.90-1.78), R2 = 0.39 3/60
Elderly subjects 53 ± 4 68 ± 7 (1.23-1.81), R2 = 0.62 4/67
Insulin-resistant subjects c 96 ± 10 121 ± 14 (0.95-1.51), R2 = 0.65 1/44
Insulin-sensitive subjects 49 ± 4 49 ± 7 (0.73-1.54), R2 = 0.44 1/43
Regression analysis was always significant (P < .0001).
a BMI ≥30 kg/m2.
b Age <41 years, >57 (lower and upper quartiles).
c M <13.0 mg min−1 kg−1, M >26.7 (lower and upper quartiles).
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(without distinction between diabetic and nondiabetic sub-
jects) also was consistently detected (P < .0001 and P < .02 for
basal and total secretion, respectively). The same was true
with respect to insulin resistance: with both methods, basal
and total insulin secretions were greater in insulin-resistant
subjects compared with insulin-sensitive subjects (P < .0001
for both). With both methods, young and elderly subjects had
similar basal insulin secretion; but the young had higher total
secretion (P < .0005). Some discrepancy was found in the
comparison between men and women, where total insulin
secretion was higher in men with the insulin method (P = .02)
but not with the C-peptidemethod (P = .2). This was explained
by similar area under the C-peptide curve in men and women
(P = .2), but a slightly higher area under the insulin curve in
men (P = .045).
The insulin method is expected to overestimate insulin
secretion under conditions of reduced insulin clearance such
as obesity and insulin resistance. To assess the degree of
overestimation, in the obese subjects (Table 3), we calculated
basal and total insulin secretion normalized to the corre-
sponding mean value in the lean group. Similarly, in the
insulin-resistant group, we normalized insulin secretion to
the mean value of the insulin-sensitive group (Table 3). With
the C-peptidemethod, basal and total insulin secretions in the
obese subjects were 1.44 and 1.24 times greater than those in
the lean subjects, respectively. The corresponding figures for
the insulin method were 1.89 and 1.67. Basal and total insulin
secretions in the insulin-resistant subjects were 1.75 and 1.96
times greater than those in the insulin-sensitive subjects with
the C-peptide method, whereas they averaged 2.05 and 2.44
with the insulin method. Therefore, the insulin method
overestimated secretion by approximately 33% in obese sub-
jects and approximately 21% in insulin-resistant subjects.4. Discussion
In this study, we present an insulin-based deconvolution
method to calculate prehepatic insulin secretion and compare
the results with those calculated using the traditional
C-peptide approach. Our purpose was not to replace the
C-peptide method, which remains the criterion standard.
However, in studies in which C-peptide is not available,
assessment of insulin secretion from plasma insulin is useful,
despite its potential limitations. It must be acknowledged that
the integral of plasma insulin concentration and that of the
secretory profile are essentially proportional because of the
use of constant kinetic parameters, and hence the former
could be assumed as a surrogate measure of the latter.
However, in data sets that lack C-peptide determination, our
method allows the application of mathematical models of
β-cell function [10,11], which have been developed in partic-
ular for the OGTT and proven to be useful in several large
studies [12-14]. In these models, it is necessary to use
prehepatic insulin secretion to obtain β-cell function parame-
ters that can be correctly interpreted and comparedwith those
of previous studies. Besides this application, the method is
valuable for reconstructing the fast secretion phenomena,
such as first-phase insulin secretion during the IVGTT. In fact,Please cite this article as: Tura A, et al, Estimation of prehe
C-peptide and insulin kinetic models, Metabolism (2011), doi:10the peak of plasma insulin does not reflect that of secretion,
which it is better estimated using our method, though with
approximately 1-minute delay. In addition to the estimation
of first-phase insulin secretion, this property could be useful
in the study of insulin secretion pulsatility [15].
The approach we have used to derive the standardized
insulin kinetics model clearly embeds approximations. In fact,
insulinkinetics are assumedtobe linearand time invariant, and
described by Eqs. (1) to (3), with F(t) constant. Thus, Eq. (1)
assumes that the time-varying hepatic insulin fractional
extraction, 1 − F(t), affects the peripheral insulin delivery but
not insulin clearance. This would be a significant limitation if
the goal were the accurate calculation of hepatic insulin
extraction. In our study, however, we aimed at providing a
reasonable estimate of prehepatic insulin secretion using
insulin concentration. The approximation of a constant F is
justified by the impossibility to predict F(t) in general; the
accuracy of this approximation is more dependent on
the insulin clearance value used in Eq. (3) (see below) than on
the approximation used in Eq. (1) and should be evaluated from
the comparisonwith the C-peptide referencemethod. Anyhow,
our estimate of the hepatic insulin fractional extraction, 1 − F―
(∼60%, Table 2), was consistent with previous studies [16,17].
Following the logic of themethod of Van Cauter et al [5], we
examined possible relationships between the insulin model
parameters and simple anthropometric or metabolic data for
possible individual adjustment of the parameters. Unfortu-
nately, we were not able to find suitable allometric equations,
as in the approach of Van Cauter et al. It should be noted that,
even in the study of Van Cauter et al [5], the correlation of the
kinetic parameters with the anthropometric parameters was
statistically significant but quite weak (R2 in linear regression
analysis ranging from 0.08 to 0.25 in the best case).
The use of constant insulin kinetic parameters makes our
method in principle analogous to the historical posthepatic
insulin secretion approaches [3,4]. However, there are some
important differences. First, the historical methods did not
propose a standardized insulin kinetic model, that is, a
method to calculate posthepatic insulin secretion in the
general case. In our study, this standardized insulin kinetic
model turned out to generate a model with constant
parameters; but this is a result of a specific and novel analysis
on a considerably large number of subjects. Second, although
by simple scaling, we have proposed a method for calculating
prehepatic insulin secretion and evaluated its performance
against the reference C-peptide technique. This approach has
not been considered in the historical studies. Last, to our
knowledge, this is the first study examining in detail the
potentialities and limitations of the insulin deconvolution
method in a large number of subjects.
For the estimation of insulin kinetic parameters, we used a
group of womenwith a history of gestational diabetes (Vienna
data set), where the main limitations are the single sex and
the relatively young age. However, for our purposes, it was
essential to analyze a sufficiently large data set generated
from 2 independent tests including both plasma insulin and
C-peptide measurements: an insulin-modified IVGTT to
derive insulin kinetic parameters and a 3-hour OGTT for
testing the method. Other advantages of the Vienna data set
were the following: (a) all tests were performed in the samepatic insulin secretion: comparison between standardized
.1016/j.metabol.2011.08.001
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assays (still a vexing problem [18]); and (b) the data set
included women with glucose levels and BMI varying over a
wide range, but without concomitant complications that
could act as confounding factors in the assessment of their
metabolic status.
Our method for calculating insulin secretion from plasma
insulin levels was then tested in an independent data set. As
shown in Fig. 4, the insulin method tended to overestimate
insulin secretion in the San Antonio data. One reason for this
overestimation is likely due to the use of different assays in
Vienna and San Antonio, resulting in a significantly lower
C-peptide to insulin ratio in San Antonio (Table 1). If the
calculated ISR from plasma insulin in San Antonio was
corrected for the differences in mean C-peptide to insulin ratio
between the 2 data sets (Table 1), total insulin secretion values
fromC-peptide and insulinwould become very similar (67 ± 3 vs
68 ± 4 nmol, respectively). In this condition, the slope of the
regression between insulin- and C-peptide–based secretion
would not be different from 1 (1.11; 95% CI, 0.97-1.24). However,
another potential explanation for theoverestimation is intrinsic
to the use of insulin, which overestimates insulin secretion in
states of reduced insulin clearance [19,20]. This known fact was
confirmed in our study because the insulin method over-
estimated total secretion inobese and insulin-resistant subjects
by approximately 33% and approximately 21%, respectively. In
these subjects, overestimation may indeed be due to reduced
insulin clearance (and hepatic extraction), not accounted for in
our model, which may be in part due to saturation phenomena
in the presenceof high insulin secretion; this is suggestedby the
Bland-Altman plot (Figs. 3 and 5), in which the larger deviation
between themethods isobservedat thehighest secretion levels.
It should also be noted that the entity of the overestimation
reported above, and evident from inspection of Table 3, refers
to differences in total secretion. If we considered point-by-
point absolute difference in the ISR, the differences in the
results between C-peptide and insulin approaches may be
even higher. This may happen if the shape of plasma
C-peptide and insulin curves differ remarkably, although it
is known that this is not a common condition [21]. On our
data, the average point-by-point difference was around 35%.
Despite the potential for overestimating the absolute ISR
with the insulinmethod, it is important to emphasize that the
method reproduces known facts about insulin secretion.
Thus, when grouping subjects by glucose tolerance, obesity,
sex, insulin sensitivity, or age, the insulin method consistent-
ly reproduced the findings of the criterion standard, C-peptide
method, both for basal and total insulin secretion. The
disparity concerning the sex differences could be attributed
to differences in the corresponding C-peptide to insulin ratio.
Another important result was that the classic relationships
between basal and total insulin secretion vs BMI and insulin
sensitivity were similarly well described using the insulin
method and the C-peptide method. This analysis reveals an
underappreciated concordance between the 2 methods.
In conclusion, we have developed an insulin-based decon-
volution method for the calculation of endogenous (prehepa-
tic) insulin secretion and compared it to the traditional
C-peptide–based method. The method can be useful for the
application of β-cell function modeling methodologies inPlease cite this article as: Tura A, et al, Estimation of prehe
C-peptide and insulin kinetic models, Metabolism (2011), doi:10studies where plasma C-peptide concentrations are not
available. However, it should be used with caution in
conditions where insulin clearance is known to be remarkably
different from the standardized value that we have used in
our approach.Funding
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